



3.3 Infectious Diseases and Immunity Area

IMMUNO-RHEUMATOLOGY GROUP

 **Publications: 30**

 **Impact Factor: 127.309**

 **Q1: 14**



PUBLICATIONS

- Balsa A, Beltrán JVT, Cáliz RC, Bernardo IM, García-Vicuna R, Rodríguez-Gómez M, Serrano MAB, Marras C, Cortina EL, Pérez-Pampin E, Vila V. Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study. *Rheumatol Int.* 2015;35(9):1525-34. Article. IF: 1.702; Q3.
- Barato SG, Mendieta ED, Martín-Mola E. Evolution in the use of musculoskeletal ultrasonography in a rheumatology unit over 14 years. *Reumatismo.* 2015;67(1):8-12. Article. Not indexed.
- Barón R, Martín-Mola E, Muller M, Dubois C, Falke D, Steigerwald I. Effectiveness and safety of tapentadol prolonged release (PR) versus a combination of tapentadol pr and pregabalin for the management of severe, chronic low back pain with a neuropathic component: A randomized, double-blind, phase 3b study. *Pain Pract.* 2015;15(5):455-70. Article. IF: 2.317; Q2.
- Bellamy N, Hochberg M, Tubach F, Martín-Mola E, Awada H, Bombardier C, Hajjaj-Hassouni N, Logeart I, Matucci-Cerinic M, van de Laar M, van der Heijde D, Dougados M. Development of multinational definitions of minimal clinically important improvement and patient acceptable symptomatic state in osteoarthritis. *Arthrit Care Res.* 2015;67(7):972-80. Article. IF: 3.229; Q2.
- Bossini-Castillo L, de Kovel C, Kallberg H, van 't Slot R, Italiaander A, Coenen M, Tak PP, Posthumus MD, Wijmenga C, Huizinga T, van der Helm-van Mil AHM, Stoeken-Rijsbergen G, Rodríguez-Rodríguez L, Balsa A, González-Álvaro I, González-Gay MA, Gómez-Vaquero C, Franke B, Vermeulen S, van der Horst-Bruinsma IE, Dijkmans BAC, Wolbink GJ, Ophoff RA, Maehlen MT, van Riel P, Merriman M, Klareskog L, Lie BA, Merriman T, Crusius JBA, Brouwer E, Martín J, de Vries N, Toes R, Padyukov L, Koeleman BPC. A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides. *Ann Rheum Dis.* 2015;74(3):e15. Article. IF: 12.384; D1.
- Falcao S, Castillo-Gallego C, Peiteado D, Branco J, Mola EM, de Miguel E. Can we use enthesis ultrasound as an outcome measure of disease activity in spondyloarthritis? A study at the Achilles level. *Rheumatology.* 2015;54(9):1557-62. Article. IF: 4.524; Q1.
- Fodil M, Teixeira VH, Chaudru V, Hilliquin P, Bombardieri S, Balsa A, Westhovens R, Barrera P, Alves H, Migliorin P, Bardin T, Cornelis F, Boudjema A, Petit-Teixeira E. Relationship between SNPs and expression level for candidate genes in rheumatoid arthritis. *Scand J Rheumatol.* 2015;44(1):2-7. Article. IF: 2.307; Q3.
- García-Bermudez M, López-Mejías R, Genre F, Castañeda S, Corrales A, Llorca J, González-Juanatey C, Ubilla B, Miranda-Fillooy JA, Pina T, Gómez-Vaquero C, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Balsa A, Pascual-Salcedo D, López-Longo FJ, Carreira P, Blanco R, Martín J, González-Gay MA. Lack of association between JAK3 gene polymorphisms and cardiovascular disease in Spanish patients with rheumatoid arthritis. *Biomed Res Int.* 2015;3:18364. Article. IF: 2.134; Q3.
- Gazal S, Sacre K, Allanore Y, Teruel M, Goodall AH, Tohma S, Alfredsson L, Okada Y, Xie G, Constantin A, Balsa A, Kawasaki A, Nicaise P, Amos C, Rodríguez-Rodríguez L, Chiochia G, Boileau C, Zhang JY, Vittecoq O, Barnette T, Gay MAG, Furukawa H, Cantagrel A, Le Loet X, Sumida T, Hurtado-Nedelec M, Richez C, Chollet-Martín S, Schaefferbeke T, Combe B, Khoryati L, Coustet B, El-Benna J, Siminovitsh K, Plenge R, Padyukov L, Martín J, Tsuchiya N, Dieude P. Identification of secreted phospho-

- protein 1 gene as a new rheumatoid arthritis susceptibility gene. *Ann Rheum Dis*. 2015;74(3):e19. Article. IF: 12.384; D1.
- González-Álvaro I, Martínez-Fernández C, Dorantes-Calderón B, García-Vicuna R, Hernández-Cruz B, Herrero-Ambrosio A, Ibarra-Barrueta O, Martín-Mola E, Monte-Boquet E, Morell-Baladrón A, Sanmartí R, Sanz-Sanz J, de Toro-Santos FJ, Vela P, Ivorra JAR, Poveda-Andrés JL, Muñoz-Fernández S. Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. *Rheumatology*. 2015;54(7):1200-9. Article. IF: 4.524; Q1.
 - Gvozdenovic E, Wolterbeek R, Allaart CF, Brenol C, Dougados M, Emery P, Ferraccioli G, van der Heijde D, Huizinga TWJ, Kay J, Mola EM, Moots RJ, da Silva JAP, Smolen J, Veale D, Landewe RBM. Assessment of global disease activity in rheumatoid arthritis by patients and physicians: differences across countries in the METEOR Database. *JCR-J Clin Rheumatol*. 2015;21(7):349-54. Article. IF: 1.245; Q4.
 - Huizinga TWJ, Conaghan PG, Martín-Mola E, Schett G, Amital H, Xavier RM, Troum O, Aassi M, Bernasconi C, Dougados M. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. *Ann Rheum Dis*. 2015;74(1):35-43. Article. IF: 12.384; D1.
 - López-Cotarelo P, Escribano-Díaz C, González-Bethencourt IL, Gómez-Moreira C, Déguiz ML, Torres-Bacete J, Gómez-Cabañas L, Fernández-Barrera J, Delgado-Martín C, Mellado M, Regueiro JR, Miranda-Carús ME, Rodríguez-Fernández JL. A novel MEK-ERK-AMPK signaling axis controls chemokine receptor CCR7-dependent survival in human mature dendritic cells. *J Biol Chem*. 2015;290(2):827-40. Article. IF: 4.258; Q1.
 - Loza E, Lajas C, Andrés JL, Balsa A, González-Álvaro I, Illera O, Jover JA, Mateo I, Orte J, Rivera J, Heredia JMR, Romero F, Martínez-López JA, Ortiz AM, Toledano E, Villaverde V, Carmona L, Castañeda S. Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis. *Rheumatol Int*. 2015;35(3):445-58. Article. IF: 1.702; Q3.
 - Maehlen MT, Olsen IC, Andreassen BK, Viken MK, Jiang X, Alfredsson L, Kallberg H, Brynedal B, Kurreeman F, Daha N, Toes R, Zhernakova A, Gutiérrez-Achury J, de Bakker PIW, Martín J, Teruel M, González-Gay MA, Rodríguez-Rodríguez L, Balsa A, Uhlig T, Kvien TK, Lie BA. Genetic risk scores and number of autoantibodies in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2015;74(4):762-68. Article. IF: 12.384; D1.
 - Montes A, Pérez-Pampín E, Navarro-Sarabia F, Moreira V, de la Sema AR, Magallares B, Vasilopoulos Y, Sarafidou T, Fernández-Nebro A, Ordóñez MD, Narváez J, Cañete JD, Márquez A, Pascual-Salcedo D, Joven B, Carreira P, Moreno-Ramos MJ, Cáliz R, Ferrer MA, García-Portales R, Blanco FJ, Magro C, Raya E, Valor L, Alegre-Sancho JJ, Balsa A, Martín J, Plant D, Isaacs J, Morgan AW, Barton A, Wilson AG, Gómez-Reino JJ, González A. Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study. *Arthritis Res Ther*. 2015;17:63. Article. IF: 3.979; Q1.
 - Morales-Santana S, Díez-Pérez A, Olmos JM, Nogues X, Sosa M, Díaz-Curiel M, Pérez-Castrillón JL, Pérez-Cano R, Torrijos A, Jodar E, del Río L, Caeiro-Rey JR, Reyes-García R, García-Fontana B, González-Macias J, Muñoz-Torres M. Circulating sclerostin and estradiol levels are associated with inadequate response to bisphosphonates in postmenopausal women with osteoporosis. *Maturitas*. 2015;82(4):402-10. Article. IF: 3.12; Q1.
 - Navarro-Compán V, de Miguel E, van der Heijde D, Landewe R, Almodóvar R, Montilla C, Beltrán E, Zarco P. Spondyloarthritis features forecasting the presence of HLA-B27 or sacroiliitis on magnetic resonance imaging in patients with suspected axial spondyloarthritis: results from a cross-sectional study in the Esperanza Cohort. *Arthritis Res Ther*. 2015;17:265. Article. IF: 3.979; Q1.
 - Navarro-Compán V, Maria Gherghe A, Smolen JS, Aletaha D, Landewe R, van der Heijde D. Relationship between disease activity indices and their individual components and radiographic progression in RA: A systematic literature review. *Rheumatology*. 2015;54(6):994-1007. Review. IF: 4.524; Q1.
 - Navarro-Compán V, Landewe R, Provan SA, Odegard S, Uhlig T, Kvien TK, Keszei AP, Ramiro S, van der Heijde D. Relationship between types of radiographic damage and disability in patients with rheumatoid arthritis in the EURIDISS Cohort: A longitudinal study. *Rheumatology*. 2015;54(1):83-90. Article. IF: 4.524; Q1.
 - Peiteado D, Villalba A, Martín-Mola E, de Miguel E. Reduction but not disappearance of Doppler signal after two years of treatment for gout. Do we need a more intensive treatment? *Clin Exp Rheumatol*. 2015;33(3):385-90. Article. IF: 2.495; Q2.
 - Plasencia C, Jurado T, Villalba A, Peiteado D, Casla MT, Nuño L, Bonilla MG, Martínez-Feito A, Martín-Mola E, Pascual-Salcedo D, Balsa A. Effect of infliximab dose increase in rheumatoid arthritis at different trough concentrations: a cohort study in clinical practice conditions. *Front Med (Lausanne)*. 2015;2:71. Article. Not indexed.
 - Plasencia C, Kneepkens EL, Wolbink G, Krieckaert CLM, Turk S, Navarro-Compán V, L'Ami M, Nurmohamed MT, van der Horst-Bruinsma I, Jurado T, Diego C, Bonilla G, Villalba A, Peiteado D, Nuno L, van der Kleij D, Rispens T, Martín-Mola E, Balsa A, Pascual-Salcedo D. Comparing tapering strategy to standard dosing regimen of tumor necrosis factor inhibitors in patients with spondyloarthritis in low disease activity. *J Rheumatol*. 2015;42(9):1638-46. Article. IF: 3.236; Q2.
 - Pontes C, Gratacos J, Torres F, Avendaño C, Sanz J, Vallano A, Juanola X, de Miguel E, Sanmartí R, Calvo G. Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with



3.3 Infectious Diseases and Immunity Area

anti-TNF (REDES-TNF): study protocol for a randomized controlled trial. *Trials*. 2015;16:370. Article. IF: 1.859; Q3.

- Riancho-Zarrabeitia L, Calvo-Río V, Blanco R, Mesquida M, Adán AM, Herreras JM, Aparicio A, Peiteado-López D, Cordero-Coma M, Serrano JLG, Ortego-Centeno N, Maíz O, Blanco A, Sánchez-Burson J, González-Suarez S, Fonollosa A, Santos-Gómez M, González-Vela C, Loricera J, Pina T, González-Gay MA. Anti-TNF-alpha therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients. *Semin Arthritis Rheu*. 2015;45(3):361-8. Review. IF: 3.946; Q2.
- Rodríguez-Rodríguez L, Ivorra-Cortés J, Carmona FD, Martín J, Balsa A, van Steenberg HW, van der Helm-van Mil AHM, González-Álvaro I, Fernández-Gutiérrez B. PTGER4 gene variant rs76523431 is a candidate risk factor for radiological joint damage in rheumatoid arthritis patients: a genetic study of six cohorts. *Arthritis Res Ther*. 2015;17:306. Article. IF: 3.979; Q1.
- Rodríguez-Rodríguez L, López-Mejías R, Fernández-Gutiérrez B, Balsa A, González-Gay MA, Martín J. Rheumatoid arthritis: genetic variants as biomarkers of cardiovascular disease. *Curr Pharm Design*. 2015;21(2):182-201. Review. IF: 3.052; Q2.
- Rodríguez-Sanz A, Martínez-Sánchez P, Prefasi D, Fuentes B, Pascual-Salcedo D, Blanco-Banares MJ, Díez-Tejedor E. Antiphospholipid antibodies correlate with stroke severity and outcome in patients with antiphospholipid syndrome. *Autoimmunity*. 2015;48(5):275-281. Article. IF: 2.917; Q2.
- Torices S, Álvarez-Rodríguez L, Grande L, Varela I, Muñoz P, Pascual D, Balsa A, López-Hoyos M, Martínez-Taboada V, Fernández-Luna JL. A Truncated variant of ASCCI, a novel inhibitor of NF-kappa B, is associated with disease severity in patients with rheumatoid arthritis. *J Immunol*. 2015;195(11):5415-20. Article. IF: 4.985; Q1.
- van den Berg R, de Hooge M, Bakker PAC, van Gaalen F, Navarro-Compán V, Fagerli KM, Landewe R, van Oosterhout M, Ramonda R, Reijnders M, van der Heijde D. Metric properties of the SPARCC score of the sacroiliac joints - data from baseline, 3-month, and 12-month follow-up in the SPACE cohort. *J Rheumatol*. 2015;42(7):1186-93. Article. IF: 3.236; Q2.